ICI such as Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors are well-established substances in the treatment of CMM [18] and show activity in mucosal melanoma as well. This evidence concerns the gene PDCD1 and mucosal melanoma.